Drug Profile
Research programme: Recombinant proenzyme cancer therapeutics - Propanc Biopharma
Alternative Names: POP1; POP1 programme - Propanc Biopharma; rec-PRPLatest Information Update: 14 Jul 2023
Price :
$50
*
At a glance
- Originator Propanc Health Group Corporation
- Developer Propanc Biopharma
- Class Antineoplastics; Enzyme precursors; Recombinant proteins
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Jul 2023 Recombinant proenzymes research programme: cancer therapeutics - Propanc Biopharma is still in preclinical phase for Solid tumors in Australia , https://www.propanc.com/product-pipeline/prp)
- 28 Nov 2021 No recent reports of development identified for research development in Cancer in Australia (Parenteral)
- 28 Nov 2021 No recent reports of development identified for research development in Cancer in Spain (Parenteral)